Bora Han

Bora Han has a diverse and extensive work experience in the biotechnology and pharmaceutical industry. They began their career at Allergan as a Senior Scientist in 2002, before moving to Amgen in 2005 as a Sr. Scientist. In 2007, Bora joined Pfizer as a Regulatory Strategy Lead and later held positions as Director and Senior Director. They then transitioned to Adheren Inc., where they served as Vice President of Preclinical Development from 2016 to 2016. Bora then joined Alexo Therapeutics as Vice President of Preclinical Safety from 2016 to 2018. Afterward, they worked at UNITY Biotechnology as Vice President of Safety and DMPK from 2018 to 2020. In 2020, Bora joined Prolynx LLC as the Senior Vice President of Translational Science and Operations. They currently hold the position of Vice President of Preclinical Development at Tallac Therapeutics, starting in 2021.

Bora Han obtained a PhD in Toxicology from the University of California, Irvine - College of Medicine, where they studied from 1996 to 1999. Prior to that, they attended UC Irvine from 1995 to 1999, although the degree name and field of study for this period are not provided. Additionally, Bora Han has a certification in DABT from the American Board of Toxicology, Inc., although the specific month and year of obtaining this certification are not mentioned.